Unique ID issued by UMIN | UMIN000051503 |
---|---|
Receipt number | R000058756 |
Scientific Title | Comparison of the utility of multiplex tests for non-small cell lung cancer with necrosis-rich tumors. |
Date of disclosure of the study information | 2023/07/03 |
Last modified on | 2023/07/02 23:32:21 |
Comparison of the utility of multiplex tests for non-small cell lung cancer with necrosis-rich tumors.
Comparison of the utility of multiplex tests for non-small cell lung cancer with necrosis-rich tumors.
Comparison of the utility of multiplex tests for non-small cell lung cancer with necrosis-rich tumors.
Comparison of the utility of multiplex tests for non-small cell lung cancer with necrosis-rich tumors.
Japan |
non-small cell lung cancer
Pneumology |
Malignancy
YES
To investigate appropriate testing in cases of necrosis-rich non-small cell lung cancer by performing and comparing various multi-gene tests on blood, FFPE and cytology specimens.
Others
Utility of various multigene tests for necrosis-rich non-small cell lung cancer.
Success rate of analysis using ODxTT and AmoyDx with FFPE specimens and Compact Panel Dx with FFPE or cytology specimens.
Comparison of success rates between ODxTT and Compact Panel Dx; comparison of success rates between ODxTT and AmoyDx; driver gene detection rates by analysis using ODxTT and AmoyDx in FFPE specimens and Compact Panel Dx using FFPE or cytology specimens.
Others,meta-analysis etc
20 | years-old | <= |
Not applicable |
Male and Female
(i) Patients whose FFPE led to a diagnosis of non-small cell lung cancer
(ii) Necrotic component >20% after macrodissection
(iii) Blood tests can be collected before treatment
(iv) Age at the time of obtaining consent must be 20 years or older
(v) Written consent to participate in this study has been obtained from the patient.
(i) Cases where it is deemed difficult to submit ODxTT and AmoyDx with FFPE specimens, and Compact Panel Dx with FFPE or cytology specimens due to sample volume, or where the aforementioned multi-gene tests make it difficult to submit other tests considered necessary in routine clinical practice.
(ii) Cases in which the tumor cell percentage is less than 30% even if macrodissection is performed.
(iii) Other cases deemed unsuitable by the physician in charge.
20
1st name | Tadashi |
Middle name | |
Last name | Sakaguchi |
Matsusaka Municipal Hospital
Department of Respiratory Medicine
515-0073
1550, Tonomachi, Matsusaka, Mie
+81598231515
iwbd0524@yahoo.co.jp
1st name | Tadashi |
Middle name | |
Last name | Sakaguchi |
Matsusaka Municipal Hospital
Department of Respiratory Medicine
515-0073
1550, Tonomachi, Matsusaka, Mie
+81598231515
mchsakaguchi@city-hosp.matsusaka.mie.jp
Matsusaka Municipal Hospital
Matsusaka Municipal Hospital
Other
Institutional review board of Matsusaka Municipal Hospital
1550, Tonomachi, Matsusaka, Mie.
0598-23-1515
mch1031@city-hosp.matsusaka.mie.jp
NO
2023 | Year | 07 | Month | 03 | Day |
Unpublished
Enrolling by invitation
2023 | Year | 06 | Month | 09 | Day |
2023 | Year | 06 | Month | 23 | Day |
2023 | Year | 07 | Month | 03 | Day |
2025 | Year | 06 | Month | 30 | Day |
The study is ongoing.
2023 | Year | 07 | Month | 02 | Day |
2023 | Year | 07 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000058756
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |